XGN - Exagen GAAP EPS of -$0.83 misses by $0.07 revenue of $12.84M beats by $4.14M
2023-03-20 16:10:12 ET
- Exagen press release ( NASDAQ: XGN ): Q4 GAAP EPS of -$0.83 misses by $0.07 .
- Revenue of $12.84M (+1.2% Y/Y) beats by $4.14M .
- Record 135,210 flagship AVISE® CTD tests, for the full year 2022, including 33,819 tests for the fourth quarter of 2022. Since the launch of AVISE® CTD in 2012, we have now delivered approximately 750,000 of these tests.
- Cash and cash equivalents were approximately $62.4 million as of December 31, 2022.
- For the first quarter 2023, we are increasing guidance to be in the range of $9.2 million to $9.7 million, up from $8.2 million to $9.2 million conveyed at the start of the quarter.
For further details see:
Exagen GAAP EPS of -$0.83 misses by $0.07, revenue of $12.84M beats by $4.14M